Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention with Iodixanol: An Observational Postauthorization Study  

作　　者：Xiaozeng Wang Dengfeng Ma Tianchang Li Bao Li Xi Su Yanqing Wu Zhimin Du Zheng Ji Ping Yang Baisong Yang Xuebin Cao Junxia Li Fengxia Hou Ziping Cheng Banglong Xu Yaling Han 

机构地区：[1]General Hospital of Northern Theater Command,Shenyang,Liaoning 110016,China [2]Taiyuan Center Hospital,Taiyuan,Shanxi 030009,China [3]Navy General Hospital of Chinese People’s Liberation Army,Beijing 100048,China [4]Shanxi Cardiovascular Hospital,Taiyuan,Shanxi 30001,China [5]Wuhan Asia Heart hospital,Wuhan,Hubei 430022,China [6]The Second Affiliated Hospital of Nanchang University,Nanchang,Jiangxi 330012,China [7]The First Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong 510120,China [8]Tangshan Gongren Hospital,Tangshan,Hebei 063000,China [9]China-Japan Union Hospital of Jilin University,Changchun,Jilin 130031,China [10]Air Force Hospital of Northern Theater Command,Shenyang,Liaoning110042,China [11]Hospital 252 of Chinese People’s Liberation Army,Baoding,Hebei 071066,China [12]General Hospital of Chinese People’s Liberation Army,Beijing 100853,China [13]Changchun Central Hospital,Changchun,Jilin 130051,China [14]The First Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230022,China [15]The Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230601,China.

出　　处：《Cardiology Discovery》2023年第2期95-101,共7页心血管病探索（英文）

基　　金：supported by the National Key Project of Research and Development Plan during the Thirteenth Five-year Plan Period(2016YFC1301300),China;Construction Program of National Clinical Priority Specialty.

摘　　要：Objective:This study aimed to evaluate the major adverse cardiovascular and cerebrovascular events(MACCEs)and overall safety profile associated with iodixanol in Chinese patients undergoing percutaneous coronary intervention(PCI).Methods:Patients at 30 centers in China registered in the OpenClinic v3.6 database from October 30,2013,to October 7,2015,were included in the study.The primary endpoint was in-hospital MACCEs including target lesion revascularization(TLR),stroke,stent thrombosis,cardiac death,and PCI-related myocardial infarction(MI)within 72 h post-PCI.Secondary endpoints were MACCEs from 72 h to 30 d post-PCI and other safety events within 30 d post-PCI.Results:A total of 3,042 patients were enrolled.The incidence of MACCEs within 72 h post-PCI was 2.33%(n=71),including cardiac death(0.03%,n=1)and PCI-related MI(2.30%,n=70).The incidence of MACCEs from 72 h to 30 d post-PCI was 0.16%(n=5),including cardiac death(0.10%,n=3),PCI-related MI(0.03%,n=1),and TLR for stent thrombosis(0.03%,n=1).The incidence of composite angiographic or procedural complications was 2.86%(n=87);233(7.86%)patients had results suggesting contrast-induced acute kidney injury.Conclusions:These findings indicate that the use of iodixanol in Chinese patients undergoing PCI is associated with a low incidence of MACCEs,confirming its safety in this population.

关 键 词：Percutaneous coronary intervention Contrast medium Adverse event Major adverse cardiovascular and cerebrovascular event Contrast-induced acute kidney injury 

分 类 号：R54[医药卫生—心血管疾病]